Investigating the level of anti-Helicobacter pylori antibodies in infected and non-infected patients with this bacterium

Document Type : Research Paper

Authors

1 Department of Microbiology, Faculty of Sciences, Agriculture and Modern Technology, Shiraz Branch, Islamic Azad University, Shiraz, Iran.

2 Department of Microbiology, College of Science, Agriculture and Modern Technologies, Shiraz Branch, Islamic Azad University, Shiraz, Iran.

3 Gasteroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

4 Department of Laboratory Sciences, School of Allied Medical Sciences, Ahvaze Jundishapur University of Medical Sciences, Ahvaze Iran.

Abstract

Introduction: Helicobacter pylori is a microaerophilic Gram-negative bacterium that is usually found in the stomach. The presence of this bacteria in the stomach can lead to gastritis and decrease gastric acid production. Also, studies have reported the relationship between this infection and gastric cancer. Early diagnosis of infection with this bacterium is crucial in its treatment. This study was conducted with the aim of investigating the level of anti-H. pylori antibodies in infected and non-infected patients.
Methods: A total of 85 patients with symptoms including 46 Hp+ and 39 Hp- samples were included in the study. Finally, the serum level of IgG and IgA antibodies was measured using an ELISA kit (Roche - Germany).
Results: The average age of the studied subjects was 43.83 ± 13.41 and 41.28 ± 12.65 in the Hp+ and Hp- groups, respectively. The Hp+ group included 17 females and 29 males; the Hp- group included 22 females and 17 males. No significant relationship between age and gender was observed in the two groups. Data analysis found that IgG and IgA levels were significantly increased in people with H. pylori infection compared to Hp- people (p<0.001). Also, the results showed no significant relationship between the level of antibodies and the gender of thepeople.
Conclusion: According to the results obtained from this research, H. pylori infection can occur at any age and gender. Considering the high prevalence of this disease and the economic and time costs, it seems necessary to conduct more studies on itand its causes.

Keywords

References

  1. Matos R, Sousa HS, Nogueiro J, Magalhães A, Reis CA, Carneiro F, et al. Helicobacter species binding to the human gastric mucosa. Helicobacter. 2022;27(1):e12867.
  2. Zhou Q, Li L, Ai Y, Pan Z, Guo M, Han J. Diagnostic accuracy of the 14C-urea breath test in Helicobacter pylori infections: a meta-analysis. Wien Klin Wochenschr. 2017;129(1-2):38-45.
  3. Xu C, Wu Y, Xu S. Association between Helicobacter pylori infection and growth outcomes in children: A meta‐analysis. Helicobacter. 2022;27(1):e12861.
  4. Crowe SE. Helicobacter pylori infection. New England Journal of Medicine. 2019;380(12):1158-65.
  5. Thung I, Aramin H, Vavinskaya V, Gupta S, Park J, Crowe S, et al. the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43(4):514-33.
  6. McFarland LV, Huang Y, Wang L, Malfertheiner P. Systematic review and meta-analysis: Multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events. UEG. 2016;4(4):546-61.
  7. Yang L, Kartsonaki C, Yao P, de Martel C, Plummer M, Chapman D, et al. The relative and attributable risks of cardia and non-cardia gastric cancer associated with Helicobacter pylori infection in China: a case-cohort study. The Lancet Public Health. 2021;6(12):e888-e96.
  8. Ford AC, Gurusamy KS, Delaney B, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori‐positive people. The Cochrane Lib. 2016.
  9. Postlewait LM, Squires MH, Kooby DA, Poultsides GA, Weber SM, Bloomston M, et al. Preoperative Helicobacter pylori infection is associated with increased survival after resection of gastric adenocarcinoma. Ann Surg Oncol. 2016;23(4):1225-33.
  10. Hu Q, Zhang Y, Zhang X, Fu K. Gastric mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori infection: a review of current diagnosis and management. Biomarker research. 2016;4(1):15.
  11. Amieva M, Peek RM. Pathobiology of Helicobacter pylori–induced gastric cancer. Gastroenterology. 2016;150(1):64-78.
  12. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2021;71(3):209-49.
  13. Wang Z, Dai J, Hu N, Miao X, Abnet CC, Yang M, et al. Identification of new susceptibility loci for gastric non-cardia adenocarcinoma: pooled results from two Chinese genome-wide association studies. Gut. 2017;66(4):581-7.
  14. Makristathis A, Hirschl AM, Mégraud F, Bessède E. Diagnosis of Helicobacter pylori infection. Helicobacter. 2019;24:e12641.
  15. Dore MP, Graham DY. Modern approach to the diagnosis of Helicobacter pylori infection. Alimentary Pharmacology & Therapeutics. 2022;55:S14-S21.
  16. Malfertheiner P, Megraud F, O'morain C, Gisbert J, Kuipers E, Axon A, et al. Management of Helicobacter pylori infection—the Maastricht V/Florence consensus report. Gut. 2017;66(1):6-30.
  17. Dinis-Ribeiro M, Areia M, De Vries A, Marcos-Pinto R, Monteiro-Soares M, O’connor A, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy. 2012;44(01):74-94.
  18. Tonkic A, Tonkic M, Lehours P, Mégraud F. Epidemiology and Diagnosis of H elicobacter pylori Infection. Helicobacter. 2012;17:1-8.
  19. Ardalan N, Abdi M, Zarif BR, Amini A, Memary F, Haydari E, et al. Prevalence of human T-lymphotropicvirus types I&II among high risk groups in Sanandaj in 2010. Scientific Journal of Kurdistan University of Medical Sciences. 2013;18(2).
  20. Burucoa C, Delchier JC, Courillon‐Mallet A, de Korwin JD, Mégraud F, Zerbib F, et al. Comparative Evaluation of 29 Commercial H elicobacter pylori Serological Kits. Helicobacter. 2013;18(3):169-79.
  21. Ueda J, Okuda M, Nishiyama T, Lin Y, Fukuda Y, Kikuchi S. Diagnostic accuracy of the E-plate serum antibody test kit in detecting Helicobacter pylori infection among Japanese children. Journal of epidemiology. 2014:JE20130078.
  22. Kishikawa H, Kimura K, Takarabe S, Kaida S, Nishida J. Helicobacter pylori antibody titer and gastric cancer screening. Disease Markers. 2015;2015.
  23. Toyoshima O, Nishizawa T, Arita M, Kataoka Y, Sakitani K, Yoshida S, et al. Helicobacter pylori infection in subjects negative for high titer serum antibody. World journal of gastroenterology. 2018;24(13):1419.
  24. Marchildon P, Balaban D, Sue M, Charles C, Doobay R, Passaretti N, et al. Usefulness of serological IgG antibody determinations for confirming eradication of Helicobacter pylori infection. The American journal of gastroenterology. 1999;94(8):2105-8.
  25. Yamaji Y, Mitsushima T, Ikuma H, Okamoto M, Yoshida H, Kawabe T, et al. Weak response of Helicobacter pylori antibody is high risk for gastric cancer: a cross-sectional study of 10,234 endoscoped Japanese. Scandinavian journal of gastroenterology. 2002;37(2):148-53.
  26. Tatemichi M, Sasazuki S, Inoue M, Tsugane S, Group JS. Clinical significance of IgG antibody titer against Helicobacter pylori. Helicobacter. 2009;14(3):231-6.
  27. Kiso M, Yoshihara M, Ito M, Inoue K, Kato K, Nakajima S, et al. Characteristics of gastric cancer in negative test of serum anti-Helicobacter pylori antibody and pepsinogen test: a multicenter study. Gastric Cancer. 2017;20(5):764-71.
  28. Sadeghi M, Aliramezani A, Hasanpour S. Study of serum levels of antibodies against Helicobacter pylori in patients of Islamshahr Health Center in Tehran. Laboratory & Diagnosis. 2020;12(48):55-61.
  29. Lagunes‐Servin H, Torres J, Maldonado‐Bernal C, Pérez‐Rodríguez M, Huerta‐Yépez S, Madrazo de la Garza A, et al. Toll‐Like Receptors and Cytokines are Upregulated during Helicobacter pylori Infection in Children. Helicobacter. 2013;18(6):423-32.
  30. Leja M, Grinberga‐Derica I, Bilgilier C, Steininger C. Epidemiology of Helicobacter pylori infection. Helicobacter. 2019;24:e12635.
  31. Saadi HMS, Saeed AY. Evaluation the Efficacy of ELISA IgG, IgM and IgA Tests for Diagnosis of Helicobacter pylori. Kurdistan Journal of Applied Research. 2018:172-6.
  32. Kibru D, Gelaw B, Alemu A, Addis Z. Helicobacter pyloriinfection and its association with anemia among adult dyspeptic patients attending Butajira Hospital, Ethiopia. BMC infectious diseases. 2014;14(1):656.
  33. Fraser AG, Scragg R, Schaaf D, Metcalf P, Grant CC. Helicobacter pylori infection and iron deficiency in teenage females in New Zealand. The New Zealand Medical Journal (Online). 2010;123(1313).
  34. Keramati M, Siadat Z, Mahmoudi M. The correlation between H. pylori infection with serum ferritin concentration and iron deficiency anemia. IJHO. 2007;28(4):016-20.
  35. Martín-de-Argila C, Boixeda D, Cantón R, Valdezate S, Mir N, De Rafael L, et al. Usefulness of the combined IgG and IgA antibody determinations for serodiagnosis of Helicobacter pylori infection. European journal of gastroenterology & hepatology. 1997;9(12):1191-6.
  36. Peura DA. Helicobacter pylori: a diagnostic dilemma and a dilemma of diagnosis. Gastroenterology. 1995;109(1):313-5.
  37. Perez-Perez GI, Dworkin BM, Chodos JE, Blaser MJ. Campylobacter pylori antibodies in humans. Annals of internal medicine. 1988;109(1):11-7.
  38. Pandya HB, Patel JS, Agravat HH. Non-invasive diagnosis of Helicobacter pylori: Evaluation of two enzyme immunoassays, testing serum IgG and IgA response in the Anand district of central Gujarat, India. Journal of clinical and diagnostic research: JCDR. 2014;8(6):DC12.
  39. Gościniak G. IgG and IgA antibodies in Helicobacter pylori infections. Zentralblatt für Bakteriologie. 1997;286(4):494-502.
  40. Watanabe T, Goto H, Arisawa T, Hase S, Niwa Y, Hayakawa T, et al. Relationship between local immune response to Helicobacter pylori and the diversity of disease: investigation of H. pylori-specific IgA in gastric juice. J Gastroenterol Hepatol. 1997;12(9-10):660-5.
  41. Hosseinzadeh M, Khosravi A, Kaikhavani S, Malekshahi S, Khorasani R. Helicobacter pylori Antibody titer in Migraine patients in Ilam. Iranian Journal of Medical Microbiology. 2010;3(4):24-30.
  42. Mazaheri S, Eslami E. Study of Helicobacter Pylori Antibody Serum Level in Patients with Migraine Headache. Avicenna Journal of Clinical Medicine. 2013;19(4):57-61.
  43. Khoshnood Mansourkhani Mohammad Javad, Sadif DM, Atapour Manijeh, Mahdi HBAM. The relative prevalence of Helicobacter pylori infection in the clients of Kerman health centers in 2000. Journal of Kerman University of Medical Sciences. 2000;9(3):140-5.
  44. Babamahmoodi F, Âjemi AG, kalhor M, Khalilian AR, shfiei GR. A sero epidemiological study of helicobacter pylori infection in Sari in 2001-2002. Journal of Mazandaran University of Medical Sciences. 2004;14(43):39-50.
  45. Choupani A, Rostami Z, Abdullahi A. SeroepidemiologicalPrevalence of Helicobacter Pylori of the Patients Referred to the Central Laboratory in South of Tehran, 2010. Medical Laboratory Journal. 2013;7(1):58-61.
  46. Shams S, Vesali Jamshid Z, Shahbazi T, Hasani M, Shams E, Ragolia S. Comparison of serum IgG and IgA levels against Helicobacter Pylori in patients with gastrointestinal symptoms. Infection Epidemiology and Microbiology. 2018;4(3):105-8.
Medical Journal of Mashhad university of Medical Sciences
Volume 66, Issue 1
May and June 2023
Pages 74-82

Files

Share

How to cite

Statistics